Skip to main content

Diabete Mellitus

3
Pipeline Programs
6
Companies
9
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Dong-A ST
Dong-A STKorea - Seoul
2 programs
1
1
DA-5218Phase 41 trial
DA-2811Phase 21 trial
Active Trials
NCT07239440Not Yet Recruiting288Est. Jun 2027
NCT07229534Not Yet Recruiting238Est. Nov 2027
Handok
HandokKorea - Seoul
1 program
1
Teneligliptin 20mg/dayPhase 11 trial
Active Trials
NCT03769870Completed30Est. Feb 2019
Abbott
AbbottABBOTT PARK, IL
4 programs
Device: FreeStyle Libre Flash Glucose Monitoring SystemN/A1 trial
FreeStyle LibreN/A1 trial
FreeStyle Libre 2N/A1 trial
FreeStyle Libre Flash Glucose Monitoring SystemN/A1 trial
Active Trials
NCT03159546Completed50Est. Aug 2017
NCT05251116Completed332Est. Aug 2022
NCT04959552Active Not Recruiting550Est. Dec 2026
+1 more trials
Senseonics
SenseonicsMD - Germantown
1 program
Continuous Glucose Monitoring SystemN/A1 trial
Active Trials
NCT07386340Recruiting80Est. May 2028
Nova Biomedical
Nova BiomedicalMA - Waltham
1 program
Glucose, CreatinineN/A1 trial
Active Trials
NCT05144971Completed175Est. Dec 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Dong-A STDA-5218
Dong-A STDA-2811
HandokTeneligliptin 20mg/day
SenseonicsContinuous Glucose Monitoring System
AbbottFreeStyle Libre
Nova BiomedicalGlucose, Creatinine
AbbottFreeStyle Libre 2
AbbottFreeStyle Libre Flash Glucose Monitoring System
AbbottDevice: FreeStyle Libre Flash Glucose Monitoring System

Clinical Trials (9)

Total enrollment: 1,815 patients across 9 trials

NCT07229534Dong-A STDA-5218

Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabetes

Start: Nov 2025Est. completion: Nov 2027238 patients
Phase 4Not Yet Recruiting
NCT07239440Dong-A STDA-2811

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Start: Nov 2025Est. completion: Jun 2027288 patients
Phase 2Not Yet Recruiting
NCT03769870HandokTeneligliptin 20mg/day

Teneligliptin and Atorvastatin DDI Study

Start: Jan 2019Est. completion: Feb 201930 patients
Phase 1Completed
NCT07386340SenseonicsContinuous Glucose Monitoring System

Gemini Study: A Prospective, Multicenter Evaluation of Performance and Safety of the Eversense Gemini System With Flash Glucose Measurement Feature

Start: Dec 2025Est. completion: May 202880 patients
N/ARecruiting
NCT05251116AbbottFreeStyle Libre

Study of an Interstitial Fluid Glucose Sensor

Start: Dec 2021Est. completion: Aug 2022332 patients
N/ACompleted
NCT05144971Nova BiomedicalGlucose, Creatinine

StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation

Start: Oct 2021Est. completion: Dec 2021175 patients
N/ACompleted
NCT04959552AbbottFreeStyle Libre 2

FSL2 Post Approval Study for Pediatric and Young Adults Patients

Start: Jun 2021Est. completion: Dec 2026550 patients
N/AActive Not Recruiting
NCT03369899AbbottFreeStyle Libre Flash Glucose Monitoring System

FreeStyle Libre Flash Glucose Monitoring System in Pediatric Populations

Start: Dec 2017Est. completion: May 201872 patients
N/ACompleted
NCT03159546AbbottDevice: FreeStyle Libre Flash Glucose Monitoring System

FreeStyle Libre Flash Glucose Monitoring System Accuracy

Start: May 2017Est. completion: Aug 201750 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,815 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.